fenoterol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
bronchodilators, phenethylamine derivatives	1155	13392-18-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: fenoterol phenoterol fenoterol hydrobromide fenoterol hydrochloride fenoterol HCl	A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic. Molecular weight: 303.36 Formula: C17H21NO4 CLOGP: 0.98 LIPINSKI: 0 HAC: 5 HDO: 5 TPSA: 92.95 ALOGS: -3.27 ROTB: 6

Molecule

Description

Molfile Inchi Smiles

Synonyms:

fenoterol
phenoterol
fenoterol hydrobromide
fenoterol hydrochloride
fenoterol HCl

A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.

Molecular weight: 303.36
Formula: C17H21NO4
CLOGP: 0.98
LIPINSKI: 0
HAC: 5
HDO: 5
TPSA: 92.95
ALOGS: -3.27
ROTB: 6

Drug dosage:

Dose	Unit	Route
0.60	mg	Inhal.aerosol
0.60	mg	Inhal.powder
4	mg	Inhal.solution
10	mg	O
10	mg	R

ADMET properties:

Show entries

Search:

Property	Value	Reference
CL (Clearance)	29 mL/min/kg	Lombardo F, Berellini G, Obach RS
BA (Bioavailability)	2 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.20 L/kg	Lombardo F, Berellini G, Obach RS
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Hosey CM, Chan R, Benet LZ
t_half (Half-life)	0.87 hours	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.53 %	Lombardo F, Berellini G, Obach RS
S (Water solubility)	0.16 mg/mL	Bocci G, Oprea TI, Benet LZ
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.08 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Showing 1 to 8 of 8 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1965	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Congenital coronary artery malformation	68.43	28.62	10	1680	138	63487194
Polyneuropathy	51.53	28.62	18	1672	14571	63472761
Pancreatic steatosis	49.19	28.62	10	1680	1006	63486326
Acute respiratory failure	48.94	28.62	22	1668	34463	63452869
Asthmatic crisis	48.80	28.62	11	1679	1802	63485530
Polyhydramnios	46.34	28.62	11	1679	2260	63485072
Arterial thrombosis	45.69	28.62	10	1680	1433	63485899
Sinus arrhythmia	45.48	28.62	10	1680	1463	63485869
Cervical incompetence	41.54	28.62	8	1682	609	63486723
Erysipelas	36.77	28.62	12	1678	7893	63479439

Showing 1 to 10 of 15 entries

Previous1 2Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blood phosphorus increased	90.02	28.23	31	2873	7690	34946337
Appendicolith	82.98	28.23	30	2874	8571	34945456
Appendicitis	67.20	28.23	30	2874	14777	34939250
Myasthenia gravis	62.45	28.23	23	2881	6917	34947110
Cardiogenic shock	61.30	28.23	34	2870	26584	34927443
Ventricular fibrillation	57.50	28.23	31	2873	22923	34931104
Stress	54.55	28.23	33	2871	30314	34923713
Dry mouth	49.62	28.23	31	2873	30134	34923893
Chronic obstructive pulmonary disease	48.98	28.23	37	2867	48881	34905146
Blood uric acid increased	48.50	28.23	21	2883	9603	34944424

Showing 1 to 10 of 22 entries

Previous1 2 3Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Appendicolith	95.87	23.91	30	4264	8521	79731573
Blood phosphorus increased	94.25	23.91	31	4263	10316	79729778
Appendicitis	69.86	23.91	30	4264	20764	79719330
Chronic obstructive pulmonary disease	64.72	23.91	46	4248	85373	79654721
Congenital coronary artery malformation	63.80	23.91	10	4284	106	79739988
Ventricular fibrillation	63.39	23.91	32	4262	31894	79708200
Myasthenia gravis	63.07	23.91	23	4271	10376	79729718
Cardiogenic shock	60.59	23.91	34	4260	41880	79698214
General physical health deterioration	55.42	23.91	71	4223	275167	79464927
Acute respiratory failure	49.60	23.91	34	4260	59507	79680587

Showing 1 to 10 of 41 entries

Previous1 2 3 4 5Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	G02CA03	GENITO URINARY SYSTEM AND SEX HORMONES OTHER GYNECOLOGICALS OTHER GYNECOLOGICALS Sympathomimetics, labour repressants
ATC	R03AC04	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Selective beta-2-adrenoreceptor agonists
ATC	R03AL01	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
ATC	R03CC04	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS FOR SYSTEMIC USE Selective beta-2-adrenoreceptor agonists
CHEBI has role	CHEBI:35522	beta-adrenergic agonists
CHEBI has role	CHEBI:35523	bronchodilator
CHEBI has role	CHEBI:35524	sympathomimetic
CHEBI has role	CHEBI:66993	tocolytic drugs
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D000322	Adrenergic Agonists

Showing 1 to 10 of 20 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Show entries

Search:

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.48	acidic
pKa2	11.02	acidic
pKa3	11.67	acidic
pKa4	12.2	acidic
pKa5	8.03	Basic

Showing 1 to 5 of 5 entries

Previous1Next

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN	AGONIST	EC50	6.90		WOMBAT-PK	IUPHAR
Beta-2 adrenergic receptor	GPCR		ADRB2_CAVPO		IC50	7.22		CHEMBL

Showing 1 to 2 of 2 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
003460	NDDF
003461	NDDF
130156-24-0	SECONDARY_CAS_RN
1944-10-1	SECONDARY_CAS_RN
203124	RXNORM
22M9P70OQ9	UNII
3073	INN_ID
3343	PUBCHEM_CID
349924004	SNOMEDCT_US
36369-23-0	SECONDARY_CAS_RN

Showing 1 to 10 of 23 entries

Previous1 2 3Next

Pharmaceutical products:

None